Norpace CR and Sodium polystyrene sulfonate
Determining the interaction of Norpace CR and Sodium polystyrene sulfonate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using sodium polystyrene sulfonate together with disopyramide. Combining these medications can increase the risk of an irregular heart rhythm that may be serious. If your doctor prescribes these medications together, you may need regular monitoring of your electrolyte (magnesium, potassium) levels as well as other tests to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or fast or pounding heartbeats during treatment with sodium polystyrene sulfonate. In addition, you should let your doctor know if you experience signs of electrolyte disturbance such as weakness, tiredness, drowsiness, confusion, muscle pain, cramps, dizziness, nausea, or vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Disopyramide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.
MANAGEMENT: Coadministration of disopyramide with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with disopyramide. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.
- "Multum Information Services, Inc. Expert Review Panel"
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: disopyramide
Brand name: Norpace, Norpace CR
Synonyms: n.a.
Generic Name: sodium polystyrene sulfonate
Brand name: Kalexate, Kayexalate, Kionex
Synonyms: Sodium Polystyrene Sulfonate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Norpace CR-Sodium Polystyrene Sulfonate Oral Powder
- Norpace CR-Sodium Polystyrene Sulfonate Powder
- Norpace CR-Sodium polystyrene sulfonate Rectal
- Norpace CR-Sodium Polystyrene Sulfonate Suspension
- Norpace CR-Sodium Sulf/Potassium Sulf/Mag Sulf/Polyethylene Glycol-Electrolyte Soln
- Norpace CR-Sodium Sulfacetamide and Sulfur Aqueous Gel
- Sodium polystyrene sulfonate-Norphyl
- Sodium polystyrene sulfonate-Norpramin
- Sodium polystyrene sulfonate-Northera
- Sodium polystyrene sulfonate-Nortrel 1/35
- Sodium polystyrene sulfonate-Nortrel 7/7/7
- Sodium polystyrene sulfonate-Nortriptyline